What We do

Leverages the latest advances in biotechnology, data science, and artificial intelligence to create innovative solutions for the most pressing challenges in life sciences. We partner with leading research institutions, pharmaceutical companies, and healthcare providers to accelerate the discovery, development, and delivery of new therapies and diagnostics for a range of diseases and conditions.
Bioventure drives short, medium and long-term growth with a

Clear Strategic Vision



Bioventure aims to expand its product portfolio by licensing products from other companies that complement its existing offerings. This will provide Bioventure with new revenue streams and allow it to enter new markets without significant R&D investment.

Product Registration

Bioventure seeks to achieve regulatory approval for its products in various markets around the world. This will allow the company to reach more customers and generate increased revenue.


Acquisition of Complements

Bioventure plans to acquire companies with products that complement its existing portfolio. This will enable the company to diversify its offerings and capture additional market share.


in Innovation

Bioventure aims to invest in innovative life science technologies and companies that have the potential to disrupt the industry. This will enable Bioventure to stay at the forefront of the industry and potentially identify new growth opportunities.
Brief Overview

Bioventure Products at a Glance

Bioventure products are typically developed by small, agile companies with a focus on innovation and scientific excellence. These companies often have a strong pipeline of products in development and are highly motivated to bring their products to market quickly and efficiently. Bioventure products may have a unique mechanism of action or address a particular subset of patients, providing a potentially significant advantage over existing treatments in terms of efficacy, safety, and patient outcomes.

In order to bring Bioventure products to market, emerging biotech companies typically partner with larger pharmaceutical companies or investors who can provide the necessary funding and expertise for clinical development, manufacturing, and commercialization. This collaboration between emerging biotech companies and larger pharmaceutical companies can facilitate the development and commercialization of innovative new products, bringing much-needed therapies to patients in need.


Biosimilars are highly similar versions of existing biologic drugs that offer several benefits to patients and the healthcare system. While they are not identical to the reference product, they undergo extensive testing to ensure their safety and efficacy. As the demand for biologic drugs continues to grow, biosimilars are expected to play an increasingly important role in providing affordable and accessible treatments for patients.


Peptides are a versatile and promising class of molecules with a wide range of potential applications in medicine and biotechnology. While there are still challenges associated with their use as drugs, ongoing research is focused on addressing these issues and unlocking the full potential of peptides as a therapeutic modality.


Oncology products are a critical component of the fight against cancer, encompassing a wide range of drugs, therapies, and technologies used in the management of this complex disease. While there is still much to learn about cancer and its treatment, ongoing research and innovation in the field of oncology offer hope for improved outcomes and a brighter future for cancer patients.

Other Therapeutic Areas

Encompass a wide range of products used in the treatment of various medical conditions. While these products may differ in their mechanisms of action and indications, they all share the common goal of improving patient outcomes and quality of life. Ongoing research and innovation in these areas offer hope for new and more effective treatments for patients around the world.


Diabetes is a complex disease that requires a multifaceted approach to management. While there is no cure for diabetes, ongoing research and innovation in the field of diabetes products offer hope for improved outcomes and quality of life for those living with this chronic condition.

Bioventure is the investment arm of

GlobalOne Healthcare Holding

In addition to licensing, the organization is committed to expanding market presence and contract manufacturing for operating companies across the Middle East, Africa, and beyond. This can facilitate the distribution of important healthcare products to regions where they may not be readily available, improving access to care and promoting better health outcomes. Through its commercial partners, the organization can also leverage local knowledge and expertise to navigate the complexities of these markets and ensure the successful introduction of new products.

Finally, the organization recognizes the importance of investing in late-stage biotech and health/medtech startups to expand its healthcare portfolio globally. By supporting the development of promising new products and technologies, the organization can contribute to the advancement of healthcare and improve outcomes for patients around the world. These investments can also generate returns for the organization and its partners, helping to fund future innovation and growth. Overall, the organization’s mandate reflects a commitment to driving innovation, improving access to care, and promoting better health outcomes for all.



For everyday care or changing care you can count on our doctors.

Market Access

You can count on us to keep you and your loved ones safe and healthy.


Cardiac rehabilitation (CR) can slow or reverse the nurse progression.